Grid Therapeutics Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

2022-11-03

抗体财报免疫疗法

DURHAM, N.C.--(BUSINESS WIRE)-- Grid Therapeutics, LLC, a clinical-stage biopharmaceutical company developing human-derived antibodies derived from single B cells of cancer patients, announced today a poster presentation at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022), to be held in Boston, Massachusetts and virtually on November 8-12, 2022. Presentation Details Title: Interim Results from a Phase IB, First-in-Human Study of a Novel Complement Factor H Inhibitor (GT103) in Patients with Refractory Non-Small Cell Lung Cancer (NSCLC) Abstract Number: 699 Presenter: Dr. Jeffrey Clarke, M.D., Duke Cancer Center Thoracic Clinic, Durham, NC. Date: Thursday, November 10, 2022, Poster Hall (Hall C) 9 a.m.– 9 p.m. EST All posters will be available to conference attendees as virtual e-posters during SITC 2022. The posters will also be available on November 10, 2022, in the News section of the Company’s website at , under Publications and Presentations. About the Study The Phase 1 open-label, dose-escalation clinical trial of GT103 is designed to assess the safety and tolerability of GT103 as a single agent. The study enrolled subjects with refractory NSCLC. Key objectives in the study include determining the recommended Phase 2 dose, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity. Please refer to for additional clinical trial details. About SITC Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC at sitcancer.org About Grid Grid Therapeutics is a clinical stage biotech company built on the innovative science developed by a team of researchers in Duke University School of Medicine. Located in Durham, North Carolina, Grid is currently using its unique platform to develop a pipeline of human derived, tumor-targeted antibodies for the treatment of a variety of cancers.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构